WO2024218649 - COMBINATION OF A PROTEIN KINASE INHIBITOR WITH IMMUNOMODULATORY AGENTS
National phase entry is expected:
Publication Number
WO/2024/218649
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053707
International Filing Date
16.04.2024
Title **
[English]
COMBINATION OF A PROTEIN KINASE INHIBITOR WITH IMMUNOMODULATORY AGENTS
[French]
COMBINAISON D'UN INHIBITEUR DE PROTÉINE KINASE AVEC DES AGENTS IMMUNOMODULATEURS
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
CHANDRAPPA DAGINAKATTE, Girish
RAMACHANDRA, Muralidhara
THIYAGARAJAN, Saravanan
AITHAL BALKUDRU, Kiran
DAS, Payel
Priority Data
202341027926
17.04.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2757 | |
| EPO | Filing, Examination, Granting | 21897 | |
| Japan | Filing, Examination, Granting | 2770 | |
| South Korea | Filing, Examination, Granting | 3457 | |
| USA | Filing, Examination, Granting | 7310 |
Total:
38,191
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a method for treating a cancer in a subject, comprising administering to the subject compound of formula (I) or a pharmaceutically acceptable salt thereof and at least an immunomodulator. The present invention also provides a combination and a kit for the treatment of cancer in a subject.[French]
La présente invention concerne une méthode de traitement d'un cancer chez un sujet, comprenant l'administration au sujet d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci et d'au moins un immunomodulateur. La présente invention concerne également une combinaison et un kit pour le traitement du cancer chez un sujet.